Meeting Report
2020–2021 Drug Updates in Hematologic Malignancies
Kirollos Hanna, PharmD, BCPS, BCOP
From M Health Fairview and Mayo Clinic College of Medicine, Maple Grove, Minnesota
Presenter’s disclosure of conflicts of interest is found at the end of this article.
J Adv Pract Oncol 2022;13(3):282–285 |
https://doi.org/10.6004/jadpro.2022.13.3.20 |
© 2022 Harborside™
ABSTRACT
During JADPRO Live Virtual 2021, Kirollos Hanna, PharmD, BCPS, BCOP, discussed the label indications of drugs and biologics in hematologic malignancies approved from late 2020 to late 2021, including mechanisms of action and various safety profiles so advanced practitioners can manage and treat patients safely with these new and approved therapeutic agents. In particular, CAR T-cell therapies were approved across many hematologic malignancies, along with PI3K inhibitors, anti-CD38 monoclonal antibodies, and immunotherapies.
For access to the full length article, please
sign in.
